ICICI Direct has recommended a hold rating on the stock with a target of Rs 520 in its November 19, 2015 research report.
Posts tagged MC
Hold Gujarat Gas; target of Rs. 520: ICICI Direct (20-11-2015)
Nifty holds 7900, Sensex firm; Midcap gains 1%, HDFC down (20-11-2015)
GAIL, Bajaj Auto, TCS, Wipro and Vedanta are top gainers while Sun Pharma, ITC, HDFC, Bharti Airtel and Axis Bank are among the losers.
Buy Apollo Hospitals; target of Rs 1360: Edelweiss (20-11-2015)
Edelweiss is bullish on APOLLO HOSPITALS ENTERPRISE and has recommended buy rating on the stock with a target of Rs 1360 in its November 15, 2015 research report.
Road tests show no improvement in call drops: TRAI chairman (20-11-2015)
Discussing the call drop situation and resistance of telecos on the compensation, RS Sharma, TRAI Chairman says that the decision was taken after consultation with stakeholders.
Buy JK Bank;target of Rs 125:Prabhudas Lilladher (20-11-2015)
Prabhudas Lilladher is bullish on Jammu Kahmir Bank and has recommended buy rating on the stock with a target of Rs 125 in its November 15, 2015 research report.
Buy Cummins India; target of Rs 1160: Edelweiss (20-11-2015)
Edelweiss is bullish on Cummins India and has recommended buy rating on the stock with a target of Rs 1160 in its November 18, 2015 research report.
Despite 3% rise, best to sell Dr Reddy’s on Nexium woes? (20-11-2015)
Brokerages are still cautious on the stock as troubles do not seem to end for the Indian pharma company.
GMR Energy arm starts 768MW power plant operation in AP (20-11-2015)
GMR Energy said current operations will continue up to March 2016, depending on gas availability and thereafter the Centre will call for a fresh round of bidding. The GREL power plant was awarded allocation of gas last month along with GMR Vemagiri Power Generation Ltd (GVPGL), which got operational recently.
ABN Amro IPO values bank at $17.9 bn (20-11-2015)
At the IPO price, ABN is valued at around 16.7 billion euros. The Dutch state is selling 20 percent in the privatization, or 23 percent including an over-allotment option, and intends to sell the rest in tranches.
US FDA approvals to see uptick from 2016: Lupin (20-11-2015)
Ramesh Swaminathan, President Finance Planning, Lupin says worldwide companies are also facing wrath of the US FDA.